Navigation Links
The First Patient Treated Using Celsense MRI Cell Tracking Technology
Date:4/11/2013

Pittsburgh, PA (PRWEB) April 11, 2013

Celsense, Inc. announced today that the first patient to have transplanted cells imaged by magnetic resonance imaging (MRI) using the company’s Cell Sense technology has been treated at the University of Pittsburgh Cancer Institute (UPCI).    The Phase 1 clinical trial was cleared by the US FDA for the purposes of developing information regarding cell migration following administration of live cells.

This application, involving the use of an autologous dendritic cell vaccine to treat colorectal cancer, is the first time the trafficking of a live cell cancer vaccine in patients has been visualized by MRI in the United States. The administration of live cell vaccines is an emerging strategy to treat a variety of cancers.

Investigators believe that the unaided trafficking of dendritic cells to the lymph node is fundamental to the success of this therapeutic strategy. "We are excited that this study is finally moving forward. While this is only the first patient to be imaged in the clinical trial, we expect that data from this study as a whole will lead to improved outcomes for patients receiving live cell vaccines for cancer," said Charlie O'Hanlon, President and CEO of Celsense.

“Where infused therapeutic cells migrate, how many go where, and how long they stay is something about which we have very little data in a clinical setting. To-date there have been few, if any, tools at our disposal to use in obtaining this information in humans,” says cell therapy industry analyst, Lee Buckler, Managing Director of the Cell Therapy Group. “Cell Sense certainly represents one of the first and only cell imaging technologies that has been cleared by a regulatory agency for human use and to that extent it signals a significant step forward in our ability to learn from what it tells us the cells do post-transplant.”

This clinical trial has been funded by an RO1 grant from the National Cancer Institute at the National Institutes of Health. The co-investigators at UPCI are Drs. Pawel Kalinski and David Bartlett. Other investigators include Dr. Eric Ahrens at Carnegie Mellon University and Dr. Amy Wesa at Celsense.

About Colorectal Cancer (CRC)
CRC is the third leading cancer in the United States and the most common form of gastrointestinal malignancy. CRC accounts for approximately 150,000 new cases annually. Immunotherapeutic interventions using live-cell DC vaccines may potentially be effective in CRC patients. To date, the inability to accurately follow the location of the cells after transfer to the patient is one of the critical bottlenecks in the development and delivery of cancer immunotherapies.

About Cell Sense
Cell Sense is a patented fluorocarbon tracer agent used to safely and efficiently label cells ex vivo without the use of transfection agents. Labeled cells are transplanted into the patient enabling researchers and clinicians to non-invasively track the administration and migration of therapeutic and/or diagnostic cells using 19F MRI or MRS. Applications include tracking cells in immunotherapy or regenerative medicine as well as diagnosis of inflammatory sites by tracking selected populations of immune cells. Cell Sense is the subject of a Drug Master File at US FDA and Health Canada, and is the only clinical grade MRI cell tracking reagent available in North America. Using software developed by Celsense, investigators can quantify the number of labeled cells in a user-specified region of interest. It is expected that in vivo cellular imaging will routinely be used to provide a surrogate biomarker for certain cellular therapeutic and drug trials.

About Celsense
Celsense, Inc. develops and offers novel pre-clinical and clinical-grade products that enable the non-invasive imaging of cells in vivo using MRI. Celsense’s mission is to be the standard for cellular imaging in human health.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10616006.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Finally, the need of nearly every woman wanting to look more beautiful is fulfilled with Crisalix, the first online direct-to-consumer 3D imaging using standard pictures
2. Dr. Ritchie Shoemaker Proudly Announces First Graduate of Shoemaker Protocol Certification Training
3. The First Dedicated Breast Cancer Cell Line Transfection Reagent
4. First Warning Systems, Inc., Appoints Veteran Medical Executive Royea as CEO
5. Seahorse Bioscience Launches First Product from the Partnership with Baystate Medical Center and UMass Amherst
6. First Time in Philadelphia Is a Success for Pittcon 2013 (Summary Report)
7. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
8. Medifirst Solutions, Inc. Announces Further Update To Shareholders
9. BioMed Realty Trust Declares First Quarter 2013 Common Stock Dividend
10. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
11. First-To-File Patent Law Is Now In Effect, But What Does it Mean?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... biotechnology acceleration company reports the Company,s CEO  was ... capital titled Accelerators Enter When VCs Fear To ... Life Science Leader magazine is an ... work for everything from emerging biotechs to Big ...
(Date:4/28/2016)... ... April 28, 2016 , ... Next week on May ... its first-in-class technologies for tissue stem cell counting and expansion to gene-editing scientists ... Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. , The attention of most ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... will hold an open house for regional manufacturers at its Maple Grove, Minnesota ... Tsugami, Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 leading suppliers of ...
(Date:4/27/2016)... ... April 27, 2016 , ... Shimadzu Scientific ... the Spring 2016 Marijuana Business Conference and Expo. Shimadzu’s high-performance instruments enable laboratories ... and more. Expo attendees can stop by booth 1021 to learn how Shimadzu’s ...
Breaking Biology Technology:
(Date:3/22/2016)... and SANDY, Utah , ... which operates the highest sample volume laboratory in ... Genomics and UNIConnect, leaders in clinical sequencing informatics and ... launch of a project to establish the informatics infrastructure ... NSO has been contracted by the Ontario ...
(Date:3/15/2016)... New York , March 15, 2016 ... new market report published by Transparency Market Research "Digital Door ... Trends and Forecast 2015 - 2023," the global digital door ... US$ 731.9 Mn in 2014 and is forecast to grow ... 2023. Growth of micro, small and medium enterprises (MSMEs) across ...
(Date:3/11/2016)... , March 11, 2016 http://www.apimages.com ) ... Cross reference: Picture is available at AP Images ( http://www.apimages.com ) ... DERMALOG will be used to produce the new refugee identity cards. ... biometric innovations, at CeBIT in Hanover next ... from DERMALOG will be used to produce the new refugee identity ...
Breaking Biology News(10 mins):